Aibo Medical Robotics was founded in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is years of scientific research and technological precipitation - that is, the founding team led by academician Guo Shuxiang, Dr. Guo Jian nearly 30 years of R & D accumulation, as well as the corresponding patent matrix.
It is reported that as early as 2008, the company's founder, academician Guo Shuxiang, pioneered the development of the world's first pan-vascular interventional surgery robot in Japan, which can be used for neurological, coronary artery, peripheral vascular angiography and treatment; in 2017, the company's team developed the principle of vascular interventional surgical robot prototype in the Tiantan Hospital in Beijing, to complete the first case of neurological intervention in the country's first clinical trials in human beings; the development of the AIBO Medical Robotics' vascular interventional surgery robot has been iterated to the third generation.
According to the relevant person in charge of Able Medical Robotics, the company's vascular interventional surgery robot is being improved towards miniaturization, lightweight, low-cost and other aspects. This year, Aibo Medical Robotics' vascular interventional surgery robot is expected to enter the registered clinical stage.
In recent years, China's vascular intervention surgery volume support climbing, but also gradually exposed to the medical resource tension, uneven distribution of doctors and patients and other problems. Neurological intervention, for example, neurological intervention is known as the crown jewel of interventional surgery, with great difficulty, high risk, long time and other characteristics. The cerebral blood vessels are curved and fragile, and the intervention operation requires high precision and is highly dependent on the doctor's personal experience and level. The time required for a neuro-intervention operation may be more than twice as long as that of a coronary intervention operation, coupled with a long training cycle for the doctors and a heavy workload accordingly. The emergence of surgical robots has made it possible for vascular interventions to be intelligent and automated, acting as the doctor's eyes, hands, and brain.
Based on the huge market demand, China's vascular interventional surgical robots market size will reach RMB 0.34 billion in 2022 and further grow to RMB 5.824 billion in 2030, with a CAGR of 90.3% from 2022 to 2030.
The head of AIBO Medical Robotics explained, "Compared to laparoscopy or orthopedics, vascular intervention is a surgical scenario that is easier and more in need of automation. The vascular intervention robot operates within the blood vessels like a self-driving car on the highway." It is reported that through the mode of master-slave separation, based on precise force feedback, medical staff can utilize the vascular interventional surgical robot of AIBO Medical Robotics to perform surgical operations outside of the catheterization room, which not only makes the interventional procedures more precise and efficient, reduces the incidence of postoperative complications in patients, but also keeps doctors away from the catheterization room and reduces radiation.
According to reports, most of the vascular interventional robots on the market at present have a single function, and can only meet the function of pushing the guidewire, but in vascular interventional surgery, especially in neurological interventions, usually require doctors to operate a variety of guidewire catheters to carry out surgery, and the operation needs to be operated catheter for multiple imaging to observe the location of the device, the vascular situation; due to the inability to realize the synergistic operation of multi-device, the existing Due to the inability to realize multi-device operation, the existing vascular interventional robots are not widely compatible with various types of vascular interventional procedures, including imaging and treatment, and have a shorter duration of operation, and also require bedside teamwork, so doctors can not really avoid exposure to radiation.
In this regard, AIBO Medical Robotics has designed a vascular intervention robot based on the concept of modularity, which can meet the collaborative operation and control of multi-catheter guidewires, and complete the composite actions of pushing, rotating, and pushing + rotating, etc. The product is compatible with all kinds of standardized guidewire catheters in the market, and can adapt to a wide range of surgical procedures, including neurological interventions, coronary interventions, and peripheral interventions. It can be regarded as a "pan-vascular intervention robot". It is reported that these procedures "will involve more than 5 million annual domestic procedures in the future". At present, AIBO Medical Robotics has established close cooperation with Shanghai Changhai Hospital, Shanghai Zhongshan Hospital, Huazhong University of Science and Technology, Union Hospital in Shenzhen and other well-known hospitals, want to find the real clinical pain points and needs through the model of the combination of medical and industrial.
From the supply side, the global vascular interventional robotics market is still in the early stages of development, with only three products approved, and no vascular interventional robots approved in China, with a certain window of market access. Nowadays, a number of domestic and foreign innovative enterprises have begun to pour into the vascular interventional surgical robotics track, such as Vimai Medical, Aopeng Medical, Microchip Robotics, RuiXin Medical and so on, and began to fight technology, team and products. Unlike the da Vinci surgical robot, which occupies half of the luminal surgical robot market, the pattern of the vascular interventional surgical robot market has not yet been finalized.
Sucking nearly 10 billion dollars in 2021, vascular intervention is the next dark horse of surgical robots? | 36 Krypton New Winds